Study S001096

RESTORE TRIAL: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

ClinicalTrials.gov record

Registration

Registration: NCT07009860
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 121
Start: 2025-06-16
Primary completion: 2027-09-30
Lead sponsor: Altimmune, Inc.
Conditions: Alcohol-associated Liver Disease
Interventions: DRUG:Pemvidutide; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Relative (%) reduction in liver stiffness by VCTE compared to baseline [Week 48 and 24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.